Switch theme
Sign up to access all valuation multiples
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
2021
n/a
LTM Revenue $66.2M
LTM EBITDA -$80.9M
$663M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kestra Medical Techs has a last 12-month revenue (LTM) of $66.2M and a last 12-month EBITDA of -$80.9M.
In the most recent fiscal year, Kestra Medical Techs achieved revenue of $59.8M and an EBITDA of -$98.0M.
Kestra Medical Techs expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kestra Medical Techs valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $66.2M | XXX | $59.8M | XXX | XXX | XXX |
| Gross Profit | $28.1M | XXX | $24.2M | XXX | XXX | XXX |
| Gross Margin | 42% | XXX | 40% | XXX | XXX | XXX |
| EBITDA | -$80.9M | XXX | -$98.0M | XXX | XXX | XXX |
| EBITDA Margin | -122% | XXX | -164% | XXX | XXX | XXX |
| EBIT | -$109M | XXX | -$106M | XXX | XXX | XXX |
| EBIT Margin | -164% | XXX | -178% | XXX | XXX | XXX |
| Net Profit | -$117M | XXX | -$114M | XXX | XXX | XXX |
| Net Margin | -176% | XXX | -190% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Kestra Medical Techs's stock price is $17.
Kestra Medical Techs has current market cap of $856M, and EV of $663M.
See Kestra Medical Techs trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $663M | $856M | XXX | XXX | XXX | XXX | $-4.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Kestra Medical Techs has market cap of $856M and EV of $663M.
Kestra Medical Techs's trades at 13.5x EV/Revenue multiple, and -7.3x EV/EBITDA.
Equity research analysts estimate Kestra Medical Techs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kestra Medical Techs has a P/E ratio of -7.3x.
See valuation multiples for Kestra Medical Techs and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $856M | XXX | $856M | XXX | XXX | XXX |
| EV (current) | $663M | XXX | $663M | XXX | XXX | XXX |
| EV/Revenue | 10.0x | XXX | 13.5x | XXX | XXX | XXX |
| EV/EBITDA | -8.2x | XXX | -7.3x | XXX | XXX | XXX |
| EV/EBIT | -6.1x | XXX | -6.7x | XXX | XXX | XXX |
| EV/Gross Profit | 23.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.3x | XXX | -8.0x | XXX | XXX | XXX |
| EV/FCF | -7.0x | XXX | -6.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKestra Medical Techs's last 12 month revenue growth is 45%
Kestra Medical Techs's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Kestra Medical Techs's rule of 40 is -139% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kestra Medical Techs's rule of X is -8% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kestra Medical Techs and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 45% | XXX | 53% | XXX | XXX | XXX |
| EBITDA Margin | -122% | XXX | -185% | XXX | XXX | XXX |
| EBITDA Growth | -2% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -139% | XXX | -139% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -8% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 218% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kestra Medical Techs acquired XXX companies to date.
Last acquisition by Kestra Medical Techs was XXXXXXXX, XXXXX XXXXX XXXXXX . Kestra Medical Techs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kestra Medical Techs founded? | Kestra Medical Techs was founded in 2021. |
| Where is Kestra Medical Techs headquartered? | Kestra Medical Techs is headquartered in United States of America. |
| Who is the CEO of Kestra Medical Techs? | Kestra Medical Techs's CEO is Mr. Brian Webster. |
| Is Kestra Medical Techs publicy listed? | Yes, Kestra Medical Techs is a public company listed on NAS. |
| What is the stock symbol of Kestra Medical Techs? | Kestra Medical Techs trades under KMTS ticker. |
| When did Kestra Medical Techs go public? | Kestra Medical Techs went public in 2025. |
| Who are competitors of Kestra Medical Techs? | Similar companies to Kestra Medical Techs include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Kestra Medical Techs? | Kestra Medical Techs's current market cap is $856M |
| What is the current revenue of Kestra Medical Techs? | Kestra Medical Techs's last 12 months revenue is $66.2M. |
| What is the current revenue growth of Kestra Medical Techs? | Kestra Medical Techs revenue growth (NTM/LTM) is 45%. |
| What is the current EV/Revenue multiple of Kestra Medical Techs? | Current revenue multiple of Kestra Medical Techs is 10.0x. |
| Is Kestra Medical Techs profitable? | Yes, Kestra Medical Techs is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kestra Medical Techs? | Kestra Medical Techs's last 12 months EBITDA is -$80.9M. |
| What is Kestra Medical Techs's EBITDA margin? | Kestra Medical Techs's last 12 months EBITDA margin is -122%. |
| What is the current EV/EBITDA multiple of Kestra Medical Techs? | Current EBITDA multiple of Kestra Medical Techs is -8.2x. |
| What is the current FCF of Kestra Medical Techs? | Kestra Medical Techs's last 12 months FCF is -$94.6M. |
| What is Kestra Medical Techs's FCF margin? | Kestra Medical Techs's last 12 months FCF margin is -143%. |
| What is the current EV/FCF multiple of Kestra Medical Techs? | Current FCF multiple of Kestra Medical Techs is -7.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
